While the clinical trial on DRP-104 (an inhibitor of glutamine-using enzymes) is still ongoing [150], the trial on CB-839 (glutaminase inhibitor) for KEAP1/NRF2Mut non-squamous NSCLC has terminated. The gene discussed is KEAP1; the disease is non-small cell lung carcinoma.